A Closer Look at the Human Gene Editing Lab
By Karla Lant,
Futurism [cites CGS' Marcy Darnovsky]
| 08. 21. 2017
As the scientific community takes in the work of the team who edited the DNA of the human embryos this month, different opinions about the safety, efficacy, and potential of the technique abound.
THE GENE EDITING PROCESS
In a lab at Oregon Health & Science University, biologist Shoukhrat Mitalipov and a team of experts have been exploring and learning how to edit the DNA in human embryos efficiently and safely. This month, they announced their successful edit and correction of a mutation which causes a heart condition that can be fatal — hopefully the first landmark step of many on the road to preventing thousands of genetic diseases with editing.
To edit an embryo, a researcher will begin by taking a human egg and monitoring it on a computer screen. They will then inject, with a pipette, donor sperm and CRISPR, microscopic chemical sequences that act as a gene-editing tool, that is designed to make the precise desired edit. CRISPR then goes to work, slicing the target defect from the DNA. After this editing process, the scientists place the embryos...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...